Pennsylvania Scientist Charged with Insider Trading in CVS-Oak Street Deal

Carlos Sacanell allegedly profited $617,000 from confidential information shared by his domestic partner, a senior executive at Oak Street Health.

Carlos Sacanell, 58, is accused of insider trading by using confidential information about CVS Health's acquisition of Oak Street Health.
Sacanell's domestic partner, a senior executive at Oak Street Health, allegedly shared non-public details about the $10.6 billion deal.
Authorities claim Sacanell bought $500,000 in Oak Street securities, making him the largest retail investor in the company's options at the time.
The SEC and federal prosecutors have charged Sacanell with insider trading and lying to the FBI about the source of his information.
Sacanell has pleaded not guilty, and his attorney argues that public information about the deal was available during the trades.